Nektar Therapeutics (0UNL.L)
USD 0.84
(0.63%)
USD 0.84
(0.63%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -243.1 Million USD | 41.23% |
| 2022 | -323.87 Million USD | 51.4% |
| 2021 | -462.96 Million USD | -30.61% |
| 2020 | -394.32 Million USD | 8.69% |
| 2019 | -382.7 Million USD | -151.68% |
| 2018 | 734.3 Million USD | 3117.92% |
| 2017 | -42.52 Million USD | 74.35% |
| 2016 | -97.26 Million USD | -541.12% |
| 2015 | -29.37 Million USD | -440.67% |
| 2014 | -2.74 Million USD | 97.38% |
| 2013 | -106 Million USD | 13.96% |
| 2012 | -124.1 Million USD | -14.03% |
| 2011 | -107.78 Million USD | -4516.3% |
| 2010 | -9.33 Million USD | 103.16% |
| 2009 | -75.71 Million USD | 57.1% |
| 2008 | 2.53 Million USD | -206.01% |
| 2007 | -7.12 Million USD | 42.58% |
| 2006 | -125.72 Million USD | -37.65% |
| 2005 | -147.06 Million USD | -61.14% |
| 2004 | -54.75 Million USD | 42.74% |
| 2003 | -47.76 Million USD | 0.17% |
| 2002 | -81.11 Million USD | -199.97% |
| 2001 | -70.31 Million USD | 782.66% |
| 2000 | -53.72 Million USD | 12.72% |
| 1999 | -23.34 Million USD | 26.87% |
| 1998 | -18.39 Million USD | -62.96% |
| 1997 | -11.28 Million USD | 5.16% |
| 1996 | -10.3 Million USD | -32.22% |
| 1995 | -7.7 Million USD | -55.17% |
| 1994 | -5.2 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -35.02 Million USD | -49.67% |
| 2024 Q1 | -32.84 Million USD | 11.58% |
| 2023 FY | - USD | 41.23% |
| 2023 Q1 | -32.98 Million USD | 12.66% |
| 2023 Q2 | -28.46 Million USD | 13.7% |
| 2023 Q3 | -28.62 Million USD | -0.58% |
| 2023 Q4 | -29 Million USD | -1.33% |
| 2022 Q2 | -45.69 Million USD | 58.82% |
| 2022 Q1 | -110.96 Million USD | 17.01% |
| 2022 FY | - USD | 51.4% |
| 2022 Q4 | -37.76 Million USD | -15.33% |
| 2022 Q3 | -32.74 Million USD | 28.34% |
| 2021 Q1 | -104.43 Million USD | 1.15% |
| 2021 Q2 | -105.81 Million USD | -1.32% |
| 2021 FY | - USD | -30.61% |
| 2021 Q3 | -113.46 Million USD | -7.23% |
| 2021 Q4 | -133.7 Million USD | -17.84% |
| 2020 Q3 | -100.14 Million USD | -44.44% |
| 2020 Q2 | -69.32 Million USD | 8.28% |
| 2020 FY | - USD | 8.69% |
| 2020 Q4 | -105.64 Million USD | -5.5% |
| 2020 Q1 | -75.58 Million USD | 21.01% |
| 2019 Q3 | -87.24 Million USD | 9.05% |
| 2019 Q1 | -105.12 Million USD | -23.42% |
| 2019 FY | - USD | -151.68% |
| 2019 Q4 | -95.69 Million USD | -9.68% |
| 2019 Q2 | -95.92 Million USD | 8.75% |
| 2018 Q4 | -85.17 Million USD | -1.28% |
| 2018 Q3 | -84.1 Million USD | -108.53% |
| 2018 FY | - USD | 3117.92% |
| 2018 Q2 | 985.7 Million USD | 1292.96% |
| 2018 Q1 | -82.62 Million USD | -1947.25% |
| 2017 Q3 | 74.87 Million USD | 250.51% |
| 2017 Q1 | -49.74 Million USD | -58.31% |
| 2017 Q2 | -49.75 Million USD | -0.01% |
| 2017 Q4 | -4.03 Million USD | -105.39% |
| 2017 FY | - USD | 74.35% |
| 2016 Q4 | -31.42 Million USD | -9.48% |
| 2016 FY | - USD | -541.12% |
| 2016 Q2 | -33.94 Million USD | -593.67% |
| 2016 Q1 | -4.89 Million USD | 83.15% |
| 2016 Q3 | -28.7 Million USD | 15.46% |
| 2015 Q3 | 4.59 Million USD | 111.38% |
| 2015 FY | - USD | -440.67% |
| 2015 Q2 | -40.36 Million USD | -187.31% |
| 2015 Q1 | 46.22 Million USD | 235.9% |
| 2015 Q4 | -29.03 Million USD | -732.24% |
| 2014 Q1 | -32.82 Million USD | 8.29% |
| 2014 Q2 | -19.56 Million USD | 40.4% |
| 2014 Q3 | 80.44 Million USD | 511.18% |
| 2014 Q4 | -34.01 Million USD | -142.28% |
| 2014 FY | - USD | 97.38% |
| 2013 Q1 | -41.03 Million USD | 4.26% |
| 2013 FY | - USD | 13.96% |
| 2013 Q4 | -35.79 Million USD | -1305.89% |
| 2013 Q3 | -2.54 Million USD | 92.14% |
| 2013 Q2 | -32.4 Million USD | 21.04% |
| 2012 Q3 | -28.65 Million USD | -25.2% |
| 2012 Q4 | -42.86 Million USD | -49.58% |
| 2012 Q1 | -32.14 Million USD | -6.16% |
| 2012 Q2 | -22.88 Million USD | 28.8% |
| 2012 FY | - USD | -14.03% |
| 2011 Q2 | -29.94 Million USD | -1.23% |
| 2011 FY | - USD | -4516.3% |
| 2011 Q4 | -30.28 Million USD | -46.17% |
| 2011 Q3 | -20.71 Million USD | 30.81% |
| 2011 Q1 | -29.57 Million USD | -723.7% |
| 2010 Q4 | -3.59 Million USD | -112.36% |
| 2010 Q1 | 1.25 Million USD | 207.92% |
| 2010 FY | - USD | 103.16% |
| 2010 Q2 | 6.44 Million USD | 413.96% |
| 2010 Q3 | -1.69 Million USD | -126.24% |
| 2009 Q1 | -25.03 Million USD | 70.7% |
| 2009 Q4 | -1.16 Million USD | 95.27% |
| 2009 Q3 | -24.58 Million USD | 16.76% |
| 2009 FY | - USD | 57.1% |
| 2009 Q2 | -29.53 Million USD | -17.96% |
| 2008 Q1 | -36.49 Million USD | -427.66% |
| 2008 FY | - USD | -206.01% |
| 2008 Q4 | -85.44 Million USD | -203.99% |
| 2008 Q3 | -28.1 Million USD | 1.18% |
| 2008 Q2 | -28.44 Million USD | 22.06% |
| 2007 Q1 | -18.62 Million USD | 21.59% |
| 2007 FY | - USD | 42.58% |
| 2007 Q4 | -6.91 Million USD | 43.69% |
| 2007 Q3 | -12.28 Million USD | 40.1% |
| 2007 Q2 | -20.5 Million USD | -10.11% |
| 2006 FY | - USD | -37.65% |
| 2006 Q1 | -24.52 Million USD | -24.77% |
| 2006 Q2 | -36.16 Million USD | -47.43% |
| 2006 Q4 | -23.75 Million USD | -38.61% |
| 2006 Q3 | -17.13 Million USD | 52.62% |
| 2005 FY | - USD | -61.14% |
| 2005 Q4 | -19.65 Million USD | -17.35% |
| 2005 Q2 | -20.18 Million USD | -35.42% |
| 2005 Q1 | -14.9 Million USD | -22.62% |
| 2005 Q3 | -16.75 Million USD | 17.0% |
| 2004 Q2 | -16.55 Million USD | -526.93% |
| 2004 Q3 | -14.44 Million USD | 12.71% |
| 2004 FY | - USD | 42.74% |
| 2004 Q4 | -12.15 Million USD | 15.86% |
| 2004 Q1 | -2.64 Million USD | 93.78% |
| 2003 Q3 | -9.72 Million USD | 28.61% |
| 2003 Q2 | -9.8 Million USD | -8.91% |
| 2003 FY | - USD | 0.17% |
| 2003 Q4 | -15.27 Million USD | -317.18% |
| 2003 Q1 | -12.97 Million USD | 47.33% |
| 2002 FY | - USD | -199.97% |
| 2002 Q4 | -24.73 Million USD | -30.5% |
| 2002 Q3 | -19.46 Million USD | -9.02% |
| 2002 Q2 | -18.06 Million USD | 6.91% |
| 2002 Q1 | -18.84 Million USD | 7.13% |
| 2001 Q3 | -19.54 Million USD | -131.01% |
| 2001 Q1 | -20.19 Million USD | 88.2% |
| 2001 FY | - USD | 782.66% |
| 2001 Q2 | -21.68 Million USD | 46.15% |
| 2001 Q4 | -23.79 Million USD | -4.75% |
| 2000 Q1 | -14.77 Million USD | -46.36% |
| 2000 FY | - USD | 12.72% |
| 2000 Q3 | -16.69 Million USD | -28.3% |
| 2000 Q4 | -17.83 Million USD | 235.45% |
| 2000 Q2 | -13 Million USD | 11.93% |
| 1999 Q4 | -10.09 Million USD | -32.22% |
| 1999 Q3 | -7.67 Million USD | -14.45% |
| 1999 FY | - USD | 26.87% |
| 1999 Q2 | -6.6 Million USD | -7.56% |
| 1999 Q1 | -6.2 Million USD | -8.87% |
| 1998 Q4 | -5.69 Million USD | 3.1% |
| 1998 Q3 | -5.8 Million USD | -47.26% |
| 1998 Q2 | -3.99 Million USD | 24.37% |
| 1998 FY | - USD | -62.96% |
| 1998 Q1 | -5.27 Million USD | -22.75% |
| 1997 Q1 | -2.74 Million USD | 36.19% |
| 1997 Q3 | -3.46 Million USD | -8.63% |
| 1997 Q4 | -4.29 Million USD | -24.14% |
| 1997 FY | - USD | 5.16% |
| 1997 Q2 | -3.18 Million USD | -16.18% |
| 1996 Q3 | -3.1 Million USD | 8.82% |
| 1996 Q4 | -4.3 Million USD | -38.71% |
| 1996 Q1 | -2.3 Million USD | 20.69% |
| 1996 FY | - USD | -32.22% |
| 1996 Q2 | -3.4 Million USD | -47.83% |
| 1995 Q1 | -2.5 Million USD | 7.41% |
| 1995 Q2 | -2.4 Million USD | 4.0% |
| 1995 Q4 | -2.9 Million USD | -26.09% |
| 1995 Q3 | -2.3 Million USD | 4.17% |
| 1995 FY | - USD | -55.17% |
| 1994 Q1 | -1 Million USD | 0.0% |
| 1994 FY | - USD | 0.0% |
| 1994 Q4 | -2.7 Million USD | -107.69% |
| 1994 Q2 | -1.2 Million USD | -20.0% |
| 1994 Q3 | -1.3 Million USD | -8.33% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| uniQure N.V. | -253.1 Million USD | 3.948% |
| Abeona Therapeutics Inc. | -50.57 Million USD | -380.715% |
| Aclaris Therapeutics, Inc. | -87.98 Million USD | -176.305% |
| Agios Pharmaceuticals, Inc. | -345.46 Million USD | 29.629% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | 8.605% |
| Cara Therapeutics, Inc. | -117.65 Million USD | -106.636% |
| Imunon, Inc. | -20.78 Million USD | -1069.78% |
| Dynavax Technologies Corporation | 9.66 Million USD | 2615.073% |
| Editas Medicine, Inc. | -163.11 Million USD | -49.038% |
| FibroGen, Inc. | -261.4 Million USD | 7.0% |
| Iovance Biotherapeutics, Inc. | -449.01 Million USD | 45.857% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | -573.763% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 158.425% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | 44.647% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 347.407% |
| Verastem, Inc. | -83.16 Million USD | -192.315% |
| Zoetis Inc. | 3.68 Billion USD | 106.597% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 105.279% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | -178.069% |
| Homology Medicines, Inc. | -47.75 Million USD | -409.061% |
| Viking Therapeutics, Inc. | -100.82 Million USD | -141.113% |
| Unity Biotechnology, Inc. | -37.28 Million USD | -552.059% |
| Perrigo Company plc | 646.2 Million USD | 137.621% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | -61.955% |
| Walgreens Boots Alliance, Inc. | -11.27 Billion USD | 97.844% |
| Illumina, Inc. | -608 Million USD | 60.015% |
| Thermo Fisher Scientific Inc. | 10.8 Billion USD | 102.251% |
| IQVIA Holdings Inc. | 3.25 Billion USD | 107.466% |
| Heron Therapeutics, Inc. | -103.79 Million USD | -134.225% |
| Waters Corporation | 1.02 Billion USD | 123.782% |
| Biogen Inc. | 2.37 Billion USD | 110.227% |
| Evolus, Inc. | -41.81 Million USD | -481.457% |
| Adicet Bio, Inc. | -136.53 Million USD | -78.055% |
| bluebird bio, Inc. | -167.16 Million USD | -45.433% |
| Geron Corporation | -174.78 Million USD | -39.092% |
| Alnylam Pharmaceuticals, Inc. | -228.12 Million USD | -6.569% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | -164.02% |
| Myriad Genetics, Inc. | -67.8 Million USD | -258.565% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 51.985% |
| Mettler-Toledo International Inc. | 1.16 Billion USD | 120.885% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | -447.086% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | 178.35% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 105.223% |
| Agilent Technologies, Inc. | 1.67 Billion USD | 114.497% |
| OPKO Health, Inc. | -65.51 Million USD | -271.065% |
| Exelixis, Inc. | 196.6 Million USD | 223.654% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | 324.426% |
| Anavex Life Sciences Corp. | -55.75 Million USD | -336.019% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | -8.052% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | -5.694% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | 153.791% |
| Blueprint Medicines Corporation | -474.61 Million USD | 48.778% |
| Insmed Incorporated | -654.73 Million USD | 62.87% |
| TG Therapeutics, Inc. | 26.1 Million USD | 1031.444% |
| Incyte Corporation | 919.42 Million USD | 126.441% |
| Emergent BioSolutions Inc. | -505.29 Million USD | 51.889% |